SCHEDULE 13G/A 0001930214 XXXXXXXX LIVE 3 Common Stock, $0.001 par value per share 09/30/2025 0001766140 Unicycive Therapeutics, Inc. 90466Y202 4300 El Camino Real, Suite 210, Los Alto CA 94022 Rule 13d-1(c) Vivo Opportunity Fund Holdings, L.P. b DE 6096175.00 0.00 6096175.00 0.00 6096175.00 N 9.99 PN (1) Represents (i) 1,789,916 shares of common stock, par value $0.001 per share (the "Common Stock") of Unicycive Therapeutics, Inc. (the "Issuer"), (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share (the "Series A-3 Preferred Stock") underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Convertible Preferred Stock, par value $0.001 per share (the "Series A-4 Preferred Stock") underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Convertible Preferred Stock, par value $0.001 per share (the "Series A-5 Preferred Stock") underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. (2) The percent of class is based on 21,491,396 shares of Common Stock outstanding as of November 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. The Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions. Vivo Opportunity, LLC b DE 6096175.00 0.00 6096175.00 0.00 6096175.00 N 9.99 OO (1) Represents (i) 1,789,916 shares of Common Stock of the Issuer, (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. (2) The percent of class is based on 21,491,396 shares of Common Stock outstanding as of November 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. The Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions. Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210, Los Alto, CA 94022 (i) Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC 192 Lytton Avenue, Palo Alto, CA 94301. Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership Vivo Opportunity, LLC, a Delaware limited liability company. The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4. The shares reported in this Schedule 13G amendment represent (i) 1,789,916 shares of Common Stock of the Issuer, (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4. The Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions. Vivo Opportunity Fund Holdings, L.P. 6,096,175 Vivo Opportunity, LLC 6,096,175 Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0 Vivo Opportunity Fund Holdings, L.P. 6,096,175 Vivo Opportunity, LLC 6,096,175 Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Vivo Opportunity Fund Holdings, L.P. /s/ Kevin Dai 11/14/2025 Vivo Opportunity, LLC /s/ Kevin Dai 11/14/2025